Ablative therapies in Barrett's esophagus

Audrey C. Pendleton; W. Scott Melvin

doi:10.1007/978-3-030-51489-1_18

Ablative therapies in Barrett's esophagus

Audrey C. Pendleton, W. Scott Melvin

Surgery

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Barrett's esophagus (BE) is a condition in which the stratified squamous epithelium that normally lines the distal esophagus lumen is replaced by metaplastic columnar epithelium that has both gastric and intestinal features. It is usually caused by persistent damage to the esophageal mucosa due to long-standing gastroesophageal reflux disease (GERD) and predisposes patients to esophageal adenocarcinoma (EAC), a cancer with a significantly increasing incidence over the past 40 years. While there are several risk factors for EAC, including smoking and obesity, GERD is the most significant one. Patients with BE have an estimated 30-125-fold greater chance of developing EAC compared to the general population.

Original language	English (US)
Title of host publication	Benign Esophageal Disease
Subtitle of host publication	Modern Surgical Approaches and Techniques
Publisher	Springer
Pages	225-231
Number of pages	7
ISBN (Electronic)	9783030514891
ISBN (Print)	9783030514884
DOIs	https://doi.org/10.1007/978-3-030-51489-1_18
State	Published - Apr 12 2021

Keywords

Ablation
Barrett
Cancer
Esophagus

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-030-51489-1_18

Cite this

@inbook{e9ebfe5a636c412e96b054a3fe6377fa,

title = "Ablative therapies in Barrett's esophagus",

abstract = "Barrett's esophagus (BE) is a condition in which the stratified squamous epithelium that normally lines the distal esophagus lumen is replaced by metaplastic columnar epithelium that has both gastric and intestinal features. It is usually caused by persistent damage to the esophageal mucosa due to long-standing gastroesophageal reflux disease (GERD) and predisposes patients to esophageal adenocarcinoma (EAC), a cancer with a significantly increasing incidence over the past 40 years. While there are several risk factors for EAC, including smoking and obesity, GERD is the most significant one. Patients with BE have an estimated 30-125-fold greater chance of developing EAC compared to the general population.",

keywords = "Ablation, Barrett, Cancer, Esophagus",

author = "Pendleton, {Audrey C.} and Melvin, {W. Scott}",

year = "2021",

month = apr,

day = "12",

doi = "10.1007/978-3-030-51489-1_18",

language = "English (US)",

isbn = "9783030514884",

pages = "225--231",

booktitle = "Benign Esophageal Disease",

publisher = "Springer",

}

TY - CHAP

T1 - Ablative therapies in Barrett's esophagus

AU - Pendleton, Audrey C.

AU - Melvin, W. Scott

PY - 2021/4/12

Y1 - 2021/4/12

N2 - Barrett's esophagus (BE) is a condition in which the stratified squamous epithelium that normally lines the distal esophagus lumen is replaced by metaplastic columnar epithelium that has both gastric and intestinal features. It is usually caused by persistent damage to the esophageal mucosa due to long-standing gastroesophageal reflux disease (GERD) and predisposes patients to esophageal adenocarcinoma (EAC), a cancer with a significantly increasing incidence over the past 40 years. While there are several risk factors for EAC, including smoking and obesity, GERD is the most significant one. Patients with BE have an estimated 30-125-fold greater chance of developing EAC compared to the general population.

AB - Barrett's esophagus (BE) is a condition in which the stratified squamous epithelium that normally lines the distal esophagus lumen is replaced by metaplastic columnar epithelium that has both gastric and intestinal features. It is usually caused by persistent damage to the esophageal mucosa due to long-standing gastroesophageal reflux disease (GERD) and predisposes patients to esophageal adenocarcinoma (EAC), a cancer with a significantly increasing incidence over the past 40 years. While there are several risk factors for EAC, including smoking and obesity, GERD is the most significant one. Patients with BE have an estimated 30-125-fold greater chance of developing EAC compared to the general population.

KW - Ablation

KW - Barrett

KW - Cancer

KW - Esophagus

UR - http://www.scopus.com/inward/record.url?scp=85148404191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148404191&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-51489-1_18

DO - 10.1007/978-3-030-51489-1_18

M3 - Chapter

AN - SCOPUS:85148404191

SN - 9783030514884

SP - 225

EP - 231

BT - Benign Esophageal Disease

PB - Springer

ER -

Ablative therapies in Barrett's esophagus

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this